Publication | Closed Access

AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

InflammationAnti-inflammatoryGastrointestinal PharmacologyImmunologyGastroenterologyPharmacologyGastrointestinal PathologyUlcerative ColitisOral AntagonistMedicineActive Ulcerative ColitisCarotegrast Methyl